聚乙二醇干扰素α-2b联合艾米替诺福韦治疗慢性乙型肝炎患者的效果
Effects of Pegylated interferon α-2b combined with Tenofovir Amibufenamide in treatment of patients with chronic hepatitis B
徐慧 1丰春玲 1林晓1
作者信息
- 1. 驻马店市中医院肝胆脾胃科,河南 驻马店 463002
- 折叠
摘要
目的:观察聚乙二醇干扰素α-2b联合艾米替诺福韦治疗慢性乙型肝炎患者的效果.方法:选取 2021 年 12 月至2022 年 9 月该院收治的 92 例慢性乙型肝炎患者进行前瞻性研究,按随机数字表法将其分为对照组(n=46)和研究组(n=46).对照组应用艾米替诺福韦治疗,研究组在对照组基础上应用聚乙二醇干扰素α-2b治疗,比较两组治疗总有效率,乙型肝炎病毒(HBV)-DNA、型肝炎病毒e抗原(HBeAg)转阴率,治疗前后肝纤维化指标[单胺氧化酶(MAO)、透明质酸(HA)、层粘连蛋白(LN)、Ⅳ型胶原(Ⅳ-C)]水平、肝功能指标[总胆汁酸(TBA)、丙氨酸氨基转移酶(ALT)、总胆红素(TBIL)]水平、肝弹性值,以及不良反应发生率.结果:研究组治疗总有效率为 91.30%(42/46),高于对照组的 65.22%(30/46),差异有统计学意义(P<0.05);研究组HBV-DNA、HBeAg转阴率均高于对照组,差异有统计学意义(P<0.05);治疗后,研究组HA、LN、MAO和Ⅳ-C水平均低于对照组,差异有统计学意义(P<0.05);治疗后,研究组ALT、TBIL、TBA水平和肝弹性值均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05).结论:聚乙二醇干扰素α-2b联合艾米替诺福韦治疗慢性乙型肝炎患者可提高治疗总有效率、HBV-DNA转阴率和HBeAg转阴率,降低肝纤维化指标水平、肝功能指标水平和肝弹性值,效果优于单纯艾米替诺福韦治疗.
Abstract
Objective:To observe effects of Pegylated interferon α-2b combined with Tenofovir Amibufenamide in treatment of patients with chronic hepatitis B.Methods:A prospective study was conducted on 92 patients with chronic hepatitis B admitted to the hospital from December 2021 to September 2022.According to the random number table method,they were divided into control group(n=46)and study group(n=46).The control group was treated with Tenofovir Amibufenamide,while the study group was treated with Pegylated interferon α-2b on the basis of that of the control group.The total effective rate of treatment,the negative rates of hepatitis B virus(HBV)-DNA and hepatitis B virus e antigen(HBeAg),the levels of liver fibrosis indexes[monoamine oxidase(MAO),hyaluronic acid(HA),laminin(LN),type IV collagen(IV-C)]and the liver function indexes[total bile acid(TBA),alanine aminotransferase(ALT),total bilirubin(TBIL)],the liver elasticity value,and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The total effective rate of treatment in the study group was 91.30%(42/46),which was higher than 65.22%(30/46)in the control group,and the difference was statistically significant(P<0.05).The negative rates of HBV-DNA and HBeAg in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of HA,LN,MAO and IV-C in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of ALT,TBIL,TBA and liver elasticity in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Pegylated interferon α-2b combined with Tenofovir Amibufenamide in the treatment of the patients with chronic hepatitis B can improve the total effective rate of treatment,the HBV-DNA negative rate and the HBeAg negative rate,reduce the levels of liver fibrosis indexes,liver function indexes and liver elasticity value.Moreover,it is superior to single Tenofovir Amibufenamide treatment.
关键词
慢性乙型肝炎/艾米替诺福韦/聚乙二醇干扰素α-2b/肝纤维化/肝功能/肝弹性/转阴率Key words
Chronic hepatitis B/Tenofovir Amibufenamide/Pegylated interferon α-2b/Liver fibrosis/Liver function/Liver elasticity/Negative rate引用本文复制引用
出版年
2024
NETL
NSTL
维普
万方数据